BRIDGEWATER, N.J. and BENGALURU, Karnataka, India, April 15, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon ...

Cantor Fitzgerald upgraded Regeneron (REGN) to Overweight from Neutral with a price target of $695, down from $800, as the analyst took over coverage of the stock. Published first on TheFly ...

April 22 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially ...

Regeneron (REGN) Pharmaceuticals announced on Friday the Food and Drug Administration has issued a complete response letter regarding the supplemental biologics license application for the ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and ...

April 18 (Reuters) - The U.S. Food and Drug Administration approved the use of Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a ...

“Regeneron is an American success story, with over 80 percent of our workforce and assets in the U.S. and all of our FDA-approved medicines invented in our New York laboratories. Our innovative ...

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to broaden its capacity. Valued at more than $3bn, the partnership is set to ...